UK unveils significant post-Brexit boost for life sciences sector

6 December 2017
parliament_li

British lawmakers have revealed details of  a new industrial strategy for the life sciences sector, aimed at supporting economic development in the wake of Brexit.

Health Secretary Jeremy Hunt and Business Secretary Greg Clark set a number of strategic goals, which include a special status for the pharmaceutical and biotech industries.

The plans, which incorporate many recommendations made in the Life Sciences Industrial Strategy, include more investment for research and development, a rise from the current level of £9.5 billion ($12.7 billion) up to £12.5 billion in 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical